BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 2020; 26(21): 2864-2876 [PMID: 32550761 DOI: 10.3748/wjg.v26.i21.2864]
URL: https://www.wjgnet.com/1007-9327/full/v26/i21/2864.htm
Number Citing Articles
1
Alessia Virzì, Victor Gonzalez-Motos, Simona Tripon, Thomas F. Baumert, Joachim Lupberger. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker DevelopmentJournal of Clinical Medicine 2021; 10(5): 977 doi: 10.3390/jcm10050977
2
Manal Sabry Mohamed, Sameh Ghaly, Karim Hamed Azmy, Ghada Abdelrahman Mohamed. Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver diseaseEgyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00189-w
3
Kawin Tangvoraphonkchai, Tanita Suttichaimongkol, Churairat Kularbkaew, Prakasit Sangaimwibool, Wattana Sukeepaisarnjaroen. Application of Mac-2 binding protein glycosylation isomer as a non-invasive biomarker for probing liver diseaseScientific Reports 2022; 12(1) doi: 10.1038/s41598-022-10744-5
4
Shereen Abou Bakr Saleh, Khaled Mohamed Abdelwahab, Asmaa Mady Mady, Ghada Abdelrahman Mohamed. The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patientsEgyptian Liver Journal 2020; 10(1) doi: 10.1186/s43066-020-00060-w